Insight Molecular Diagnostics Inc.
$3.99
▲
9.3%
2026-04-21 07:29:00
imdxinc.com
NCM: IMDX
Explore Insight Molecular Diagnostics Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$128.35 M
Current Price
$3.99
52W High / Low
$8.51 / $2.33
Stock P/E
—
Book Value
$-1.1
Dividend Yield
—
ROCE
-223.51%
ROE
229.65%
Face Value
—
EPS
$-1.65
Exp Qtr EPS
—
Sector
Healthcare
Industry
Diagnostics & Research
Employees
55
Beta
1.53
Debt / Equity
-0.11
Current Ratio
1.27
Quick Ratio
1.23
Forward P/E
-3.77
Price / Sales
25.15
Enterprise Value
$93.89 M
EV / EBITDA
-3.32
EV / Revenue
23.15
Rating
Buy
Target Price
$8.33
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Check-Cap Ltd. | $1.9 | — | $13.56 M | — | 659.83% | -1.3% | $3.92 / $0.59 | $0.64 |
| 2. | BillionToOne, Inc. | $86.97 | 489.81 | $3.65 B | — | 2.74% | 2.3% | $138.7 / $61.96 | $10.48 |
| 3. | Revvity, Inc. | $93.89 | 28.42 | $10.54 B | 0.3% | 3.29% | 3.22% | $118.3 / $81.36 | $64.57 |
| 4. | FONAR Corporation | $18.8 | 15.61 | $117.93 M | — | 5.81% | 6.01% | $18.86 / $12 | $27.01 |
| 5. | Prenetics Global Limited | $18.2 | — | $300.05 M | — | -28.75% | -31.79% | $23.63 / $3.84 | $10.89 |
| 6. | Thermo Fisher Scientific Inc. | $521.21 | 29.42 | $194.29 B | 0.36% | 8.52% | 13.02% | $643.99 / $385.46 | $141.96 |
| 7. | Illumina, Inc. | $131.09 | 24.09 | $19.95 B | — | 16.15% | 33.36% | $155.53 / $69.83 | $17.8 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 1.14 M | 0.26 M | 0.52 M | 2.14 M | 1.49 M | — |
| Operating Profit | -9.95 M | -7.67 M | -6.97 M | -5.92 M | -5.42 M | — |
| Net Profit | -22.95 M | -10.85 M | -9.74 M | -6.67 M | -33.51 M | — |
| EPS in Rs | -0.71 | -0.34 | -0.3 | -0.21 | -1.04 | -0.98 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 4.05 M | 1.88 M | 1.5 M | 0.96 M |
| Operating Profit | -30.58 M | -23.25 M | -22.42 M | -28.85 M |
| Net Profit | -50.22 M | -60.66 M | -27.78 M | -72.9 M |
| EPS in Rs | -1.56 | -1.89 | -0.86 | -2.27 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 25.76 M | 35.08 M | 74.89 M | 100.09 M |
| Total Liabilities | 57.22 M | 47.35 M | 54.42 M | 65.8 M |
| Equity | -31.46 M | -12.27 M | 20.47 M | 34.29 M |
| Current Assets | 15.31 M | 11.76 M | 10.7 M | 25.54 M |
| Current Liabilities | 12.07 M | 7.28 M | 7.19 M | 12.11 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -22.18 M | -20.69 M | -23.32 M | -45.57 M |
| Investing CF | -3.19 M | -0.51 M | -0.93 M | -4.34 M |
| Financing CF | 28.07 M | 20.43 M | 12.19 M | 35.81 M |
| Free CF | -25.37 M | -21.2 M | -23.61 M | -49.91 M |
| Capex | -3.19 M | -0.52 M | -0.28 M | -4.34 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 25.15% | 56.89% | — | — |
| Earnings Growth % | -118.36% | 61.89% | — | — |
| Profit Margin % | -3225.04% | -1848.37% | -7609.81% | — |
| Operating Margin % | -1235.89% | -1491.48% | -3011.69% | — |
| Gross Margin % | 39.34% | 27.48% | -1.88% | — |
| EBITDA Margin % | -3137.43% | -1538.46% | -1389.25% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2023-07-25 | 1:0.05 |